A5087396617- Gut microbiota and health
- Oral health in cancer treatment
- Gastric Cancer Management and Outcomes
- Clostridium difficile and Clostridium perfringens research
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Neutropenia and Cancer Infections
- Head and Neck Cancer Studies
- Mycobacterium research and diagnosis
- Barrier Structure and Function Studies
- Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Gastrointestinal motility and disorders
- Immune Response and Inflammation
- Ferroptosis and cancer prognosis
- Diet and metabolism studies
- Chemotherapy-related skin toxicity
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chronic Lymphocytic Leukemia Research
- Cannabis and Cannabinoid Research
- Adipose Tissue and Metabolism
- Cancer, Stress, Anesthesia, and Immune Response
- Tryptophan and brain disorders
- Cancer survivorship and care
- Lung Cancer Treatments and Mutations
The University of Queensland
2021-2025
The University of Adelaide
2016-2024
University of South Australia
2022
South Australian Health and Medical Research Institute
2022
Royal Adelaide Hospital
2022
Retina Institute
2021
Strong epidemiological data indicate that chemotherapy-induced gut toxicity and pain occur in parallel, indicating common underlying mechanisms. We have recently outlined evidence suggesting TLR4 signaling may contribute to both side effects. therefore aimed determine if genetic deletion of improves pain. Forty-two female wild-type (WT) 42 Tlr4 null (-/-) BALB/c mice weighing between 18 25 g (10-13 weeks) received a single 270 mg/kg (i.p.) dose irinotecan hydrochloride or vehicle control...
Abstract We have previously shown increased intestinal permeability, to 4-kDa FITC-dextran, in BALB/c mice treated with irinotecan. Importantly, genetic deletion of Toll-like receptor 4 (TLR4; Tlr4−/−) protected against loss barrier function, indicating that TLR4 is critical tight junction regulation. The current study aimed (i) determine the molecular characteristics junctions wild-type and Tlr4−/− (ii) characterize secretory profile distal colon. Forty-two female 42 weighing between 18 25...
Dacomitinib—an irreversible pan‐ErbB tyrosine kinase inhibitor (TKI)—causes diarrhoea in 75% of patients. Dacomitinib‐induced has not previously been investigated and the mechanisms remain poorly understood. The present study aimed to develop an in‐vitro in‐vivo model dacomitinib‐induced investigate underlying mechanisms. T84 cells were treated with 1‐4 μM dacomitinib resistance viability measured using transepithelial electrical (TEER) XTT assays. Rats 7.5 mg/kg daily via oral gavage for 7...
Type 1 diabetes (T1D) is linked to an altered gut microbiota characterized by reduced short-chain fatty acid (SCFA) production. Oral delivery of a SCFA-yielding biotherapy in adults with T1D was followed increased SCFAs, and immunoregulation, as well delaying preclinical models. Here, we show that SCFA-biotherapy humans accompanied remodeling the proteome mucosal immune homeostasis. Metabolomics showed arginine, glutamate, nucleotide tryptophan metabolism were enriched following...
Neratinib is a pan-ErbB tyrosine kinase inhibitor used for extended adjuvant treatment of HER2-positive breast cancer. Diarrhea the main adverse event associated with neratinib treatment. We aimed here to determine whether antibiotic-induced gut microbial shifts altered development neratinib-induced diarrhea.Female Albino Wistar rats (total n = 44) were given antibiotics (vancomycin, neomycin, or cocktail vancomycin, neomycin and ampicillin) in drinking water four weeks, then treated daily...
Tight junction and epithelial barrier disruption is a common trait of many gastrointestinal pathologies, including chemotherapy-induced gut toxicity. Currently, there are no validated in vitro models suitable for the study mucosal damage that allow paralleled functional structural analyses tight integrity. We therefore aimed to determine if transparent, polyester membrane insert supports polarized T84 monolayer with phenotypically normal junctions. cells (passage 5-15) were seeded into...
Abstract Purpose Adverse effects following fluoropyrimidine-based chemotherapy regimens are common. However, there no current accepted diagnostic markers for prediction prior to treatment, and the underlying mechanisms remain unclear. This study aimed determine genetic non-genetic predictors of adverse effects. Methods Genomic DNA was analyzed 25 single nucleotide polymorphisms (SNPs). Demographics, comorbidities, cancer regimen types, effect data were obtained from clinical records 155...
Toll-like receptor 4 (TLR4) is a highly conserved immunosurveillance protein of innate immunity, displaying well-established roles in homeostasis and intestinal inflammation. Current evidence shows complex relationships between TLR4 activation, maintenance health, disease progression; however, it commonly overlooks the importance site-specific expression. This omission has potential to influence translation results as previous differing distinct that exhibits are dependent on its...
Abstract Purpose Neratinib, a small-molecule tyrosine kinase inhibitor (TKI) that irreversibly binds to human epidermal growth factor receptors 1, 2 and 4 (HER1/2/4), is an approved extended adjuvant therapy for patients with HER2 -amplified or -overexpressed ( -positive) breast cancers. Patients receiving neratinib may experience mild-to-severe symptoms of gut toxicity including abdominal pain diarrhoea. Despite being highly prevalent complication in health, the biological processes...
Abstract Purpose Mounting evidence suggests the gut microbiome influences radiotherapy efficacy and toxicity by modulating immune signalling. However, its contribution to outcomes in head neck cancer (HNC) is yet be investigated. This study, therefore, aimed uncover associations between an individual’s pre-therapy microbiota i) severity of radiotherapy-induced oral mucositis (OM), ii) recurrence risk patients with HNC. Methods In this prospective pilot 20 HNC scheduled receive or...
Abstract Introduction Neratinib is an irreversible pan-HER tyrosine kinase inhibitor used for treatment of HER2+ breast cancer. Diarrhea a common toxicity observed with this class agents. We have previously shown that neratinib-induced diarrhea associated alterations to the gut microbiome in rat model [Secombe et al. 2020]. This study aimed evaluate contribution specific microbiota development using different classes oral antibiotics. Methods Female Albino Wistar rats (n=44) were treated...